NEW ORLEANS, Sept. 22, 2017 /PRNewswire/ -- ClaimsFiler,
a FREE shareholder information service, reminds investors that they
have until October 23, 2017 to
file lead plaintiff applications in a securities class action
lawsuit against Teva Pharmaceutical Industries Limited (NYSE:
TEVA), if they purchased the Company's American Depository Shares
("ADSs") and/or shares on the Tel Aviv Stock Exchange between
November 15, 2016 and August 2, 2017, inclusive (the "Class Period").
This action is pending in the United States District Court for the
Eastern District of Pennsylvania.
Get Help
Teva Pharmaceutical investors should visit us at
https://www.claimsfiler.com/cases/view-teva-pharmaceutical-industries-ltd-american-depository-shares-securities-litigation
or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Teva Pharmaceutical and certain of its executives are charged
with failing to disclose material information during the Class
Period, violating federal securities laws.
On August 3, 2017, Teva disclosed
the recording of a goodwill impairment charge of $6.1 billion for Q2 2017 related to the
acquisition of Actavis Generics as a result of poor performance in
its U.S. generics sector, as well as lower overall expected poor
performance due to increased competition and delays in product
launches.
On this news, the price of Teva Pharmaceutical's shares
plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information
source to help retail investors recover their share of billions of
dollars from securities class action settlements. ClaimsFiler's
team of experts monitor the securities class action landscape and
cull information from a variety of sources to ensure comprehensive
coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
View original
content:http://www.prnewswire.com/news-releases/teva-pharmaceutical-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-teva-pharmaceutical-industries-limited---teva-300524202.html
SOURCE ClaimsFiler